Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix

SUPING YANG¹, MINICA LONG¹, SOUVENIR D. TACHADO² and SEYHA SENG¹,²

Divisions of ¹Experimental Medicine and ²Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Received April 30, 2014; Accepted January 7, 2015

DOI: 10.3892/mmr.2015.4302

Abstract. Prostate cancer (PCa) is the second leading cause of cancer-related mortality among American males. Studies suggest that cigarette smoking is associated with the progression of PCa; however, the molecular mechanisms underlying this process have not been extensively investigated. PCa progression is characterized by increased cell migration and alterations in extracellular matrix (ECM-) and cell adhesion molecule (CAM-)related gene expression. In the present study, the influence of cigarette smoke medium (SM) on cell migration and on the expression of ECM- and CAM-related genes in PC3 prostate adenocarcinoma cells was investigated. According to a wound-healing assay, SM treatment promoted PC3 cell migration. RNA expression levels from SM-treated and control cells were analyzed using a polymerase chain reaction (PCR) array. Of 84 genes analyzed, 27.38% (23/84) exhibited a ≥2-fold change in threshold cycle in PC3 cells following 0.5% SM treatment. Functional gene grouping analysis demonstrated that SM treatment modulated the RNA transcription of approximately 18.4% of CAMs and 33.93% of ECM-related genes. Quantitative PCR analysis showed that SM treatment led to a significant decrease in transcription levels of the following genes: Collagen 5 α-1(V), connective tissue growth factor, integrin β-2, kallmann syndrome 1, laminin α 3, matrix metalloepitidase 7 (MMP7), MMP13, secreted protein acidic cystine-rich, thrombospondin-2 and versican; and that SM significantly increased the transcription levels of MMP2 and MMP12. Furthermore, MMP2 knockdown significantly reduced the migration of SM-treated PC3 cells. The present study provides novel insights into the association of cigarette smoking with PCa progression, via the alteration of ECM/CAM interactions.

Introduction

Prostate cancer (PCa) is the most common tumor in males in the USA, with an estimated 240,890 new cases and 33,720 mortalities related to PCa in 2011 (1). However, few risk factors have been identified beyond age and family history (2,3). Despite a proven link between cigarette smoking and a number of types of tumors (4), the association between cigarette smoking and PCa remains unresolved. Observational case-control studies investigating the association between cigarette smoking and PCa have produced inconclusive results (5). Epidemiological studies suggest that the results of investigations into the correlation between cigarette smoking and the incidence of PCa may differ from the results of those measuring PCa-related mortality (6). An observational cohort study confirmed that while smoking does not appear to be associated with PCa incidence, there is increased mortality due to PCa among heavy smokers (7). Furthermore, cigarette smokers have a higher risk of developing advanced stage and high-grade PCa, as compared with non-smokers (8). Hence, cigarette smoking is a potential contributing factor to PCa progression.

Tumor progression is a multistep process that includes cell migration, invasion and metastasis, to which alterations in the expression of extracellular matrix (ECM) and cell adhesion molecule (CAM)-related genes contribute (9). During PCa progression, tumor cell migration and invasion occur following the degradation of the ECM, which is composed of collagen, proteoglycans, fibronectin, laminin and other glycoproteins (9-13). Tumor metastasis involves the detachment of cancer cells from the primary tumor, disruption of the basement membrane and invasion of the surrounding stroma by tumor cells. Cancer cells enter the vascular and lymphatic systems and distal sites, including the liver, lungs and brain, where they extravasate, proliferate and undergo angiogenesis (9,14-16). ECM proteins such as matrix metalloproteinases (MMPs) are associated with tumor growth, cancer progression and metastasis (17-23).

Tobacco smoke contains at least 3,500 chemical compounds, many of which are toxic, carcinogenic and/or mutagenic. It consists of a particulate solid phase (tar) and a gaseous phase, containing volatile organic compounds (VOCs), free radicals and other volatile and semi-volatile compounds (24,25). Exposing prostate cancer cells to cigarette smoke promotes cell proliferation and the secretion of...
vascular endothelial growth factor (VEGF), a potent angiogenic factor (26). Angiogenesis is the process of new blood vessel formation, which is fundamental to the progression, invasion, and metastasis of numerous cancers, including PCa (27).

Interaction between the ECM and CAMs helps determine tissue shape, structure and cellular function. ECM and CAMs are involved in a range of disorders and diseases. ECM- and CAM-related gene expression on cell surfaces is involved in pathophysiological processes, such as wound healing, inflammation, and disease (9,28-34). Levels of ECM and CAM-related gene expression vary. For example, studies have shown that an increase in the expression of ECM-related genes, including MMP2 and MMP9, promotes cell invasion and the progression of PCa (35-37). The transition from healthy prostatic intraepithelial neoplasia to invasive PCa is associated with a decrease in the expression of MMP7 and the cell matrix adhesion protein, integrin β 4 (ITGB4) (38). The loss of cell adhesion molecules, such laminin α 3 (LAMA3), is associated with high Gleason scores, high preoperative prostate-specific antigen (PSA) levels and more advanced stages of PCa (39).

Cigarette smoke enhances prostate cancer cell proliferation and VEGF secretion (26). The present study examined the direct effects of cigarette smoke on cell migration, and the expression of ECM- and CAM-related genes in PC3 cells.

**Materials and methods**

**Preparation of SM.** 3R4F cigarettes (Reference Cigarette Program, University of Kentucky Research Institute; Lexington, KY, USA) contained 11.0 mg/cigarette (mg/cig) total particulate matter (TPM), 9.4 mg/cig tar, 0.73 mg/cig nicotine, and 12 mg/cig carbon monoxide (CO). SM was generated by collecting whole smoke from 20 reference cigarettes into 100 ml of cell culture media. Briefly, cigarette smoke from 20 cigarettes was bubbled into cell culture medium. The medium was then filtered, and was designated SM for 24 h, after which, cells that had migrated into the gaps were counted using a microscope (Diaphot 300; Nikon Corporation, Tokyo, Japan).

**RNA isolation.** Isolation of total RNA was performed using TRIzol® Reagent (cat. no. 15596-026; Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Cells were seeded on 6-well plates and treated with SM or F12K medium supplemented with 0.5% FBS. Subsequently, chloroform (0.2 ml; Sigma-Aldrich, St. Louis, MO, USA) was added to the wells. Samples were incubated at room temperature for 3 min, and centrifuged at 12,000 x g at 4˚C for 15 min. Subsequently, isopropanol (0.5 ml; Thermo Fisher Scientific, Waltham, MA, USA) was added to the supernatant. Following incubation at room temperature for 10 min, samples were centrifuged at 12,000 x g at 4˚C for 10 min. The pellets were washed with 75% ethanol, dissolved in RNAse-free water (Thermo Fisher Scientific) and incubated at 60˚C for 10 min.

**Gene expression profiling.** Cells were treated with 0.5% SM for 24 h. Subsequently, total RNA was extracted using TRIzol and an RNeasy mini kit (cat. no. 74104; Qiagen, Valencia, CA, USA). RNA integrity was assessed using the bioanalyzer ‘Agilent 2200 Tape Station’ (Agilent Technologies, Oxford, UK). The expression of 84 CAM- and ECM-related genes were profiled using an RT² Profiler Polymerase Chain Reaction (PCR) Array for human extracellular matrix and adhesion molecules, according to the manufacturer's instructions (cat. no. PAHS-013A; SABiosciences, Qiagen). The gene expression of 25 µg RNA per plate was measured. RNA was converted into cDNA using a reverse transcription cocktail (cat.no.33040.Qiagen) at 42˚C for 15 min. cDNA was then mixed with 2 x SABioscience RT PCR Master Mix (cat.no.330520, Qiagen) and subjected to PCR amplification using ABI7300 and ABI7500 platforms (AB Applied Biosystems, Foster City, CA, USA).

**siRNA transfection.** Small interfering RNA for MMP2 (MMP2 siRNA; cat. no. sc-29398; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) designed to knock down human MMP2 expression was resuspended to a final 10 µM concentration in a buffer containing 10µM Tris-HCl, 20 mM NaCl, and 1 mM EDTA at pH 8.0. For a control, scrambled siRNA (cat. no. sc-37007, Santa Cruz Biotechnology, Inc.) was prepared and used in the same condition. siRNA transfection was performed according to the manufacturer's instructions. In brief, PC3 cells were washed with siRNA transfection medium (Santa Cruz Biotechnology, Inc.) and incubated at 37˚C in 200 µl transfection medium containing 0.8 µM of MMP2 siRNA or scrambled siRNA (siCTRL). Following 24 h of transfection, MMP2 expression was assessed using western blot analysis and a wound healing assay was performed.

**Wound healing assay.** A scratch-wound assay was performed as previously described by Rodriguez et al (40) in order to assess cell migration in the presence of SM. Following incubation, when cells had reached ~100% confluence, they were washed with serum-free F12K medium, and replenished with ATCC-formatted medium containing 0.5% FBS. The cells were cultured for 24 h. Subsequently, a sterile 20 ml pipette tip was used to scratch the monolayer of cells in two perpendicular straight lines through the center of the wells. Wells were gently washed with serum-free culture, medium replenished with the medium containing 0.5% FBS and treated with 0 (control), 0.2, 0.5, or 1% SM in cell culture medium. Cells were cultured for 24 h, after which, cells that had migrated into the gaps were counted using a microscope (Diaphot 300; Nikon Corporation, Tokyo, Japan).
Ct values were converted to linear values using the equation 
\[2^{-\Delta \text{Ct}}\]. P-values were calculated using Student's t-test and a 95% confidence interval (CI). Changes in gene expression were expressed as fold change (FC) and fold regulation (FR). The PCR analysis was conducted using web-based applications for RT2 Profiler PCR Array Data Analysis version 3.5 (http://www.sabiosciences.com/RTPCR.php; Qiagen).

**qPCR analysis.** PCR reactions were performed using Power SYBR Green PCR Master Mix (cat. no. 4309155; AB Applied Biosystems, Warrington, UK) containing RT enzyme mix (cat. no. 4389988, AB Applied Biosystems). RNA samples were subjected to qPCR amplification using the ABI 7300 cycler (AB Applied Biosystems). Using quantitative primers, the thermal cycler conditions were as follows: 48°C for 30 min and 95°C for 10 min, followed by 42-52 cycles at 95°C for 15 sec and 60°C for 1 min.

**Statistical analysis.** Ct value calculations and statistical analyses were performed using a web-based application (SA Bioscience) as described above. Statistical significance was determined using Student's t-test. Data represent the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

### Results

**SM-mediated migration of PC3 cells.** In order to examine the influence of cigarette smoke on PC3 cell migration, the cells were cultured on 12-well plates. Cells were treated with 0 (negative control), 0.2, 0.5, 1 or 2% SM, and cells that had migrated into the gap were subsequently counted. PC3 cell migration was significantly greater following 0.2, 0.5, and 1% SM treatment compared with the migration of 0% SM-treated cells or control counterparts (Fig. 1). It is notable that PC3 cell migration was significantly lower following 1% SM treatment compared with 0.2 and 0.5% SM treatment. Furthermore, PC3 cell migration was significantly lower in 2% SM-treated cells compared with that of the control cells. Since 0.5% SM induced the greatest increase in cell migration compared with control cells, 0.5% SM was used for the remaining experiments in the present study.

**SM-modulated changes in the expression of CAM- and ECM-related genes.** ECM- and CAM-related genes are

| Gene       | FC  | FR   | Unigene Accession |
|------------|-----|------|-------------------|
| CLEC3B     | 0.43| -2.33| Hs.476092 NM_003278 |
| CNTN1      | 0.33| -2.99| Hs.143434 NM_001843 |
| COL1A1     | 2.28| 2.28 | Hs.523446 NM_080629 |
| COL1A4     | 0.43| -2.34| Hs.409662 NM_021110 |
| COL1A6     | 0.47| -2.14| Hs.368921 NM_001856 |
| COL1A1     | 0.49| -2.03| Hs.172928 NM_000088 |
| COL5A1     | 0.49| -2.04| Hs.210283 NM_000093 |
| CTGF       | 0.47| -2.11| Hs.591346 NM_01901 |
| CTNNA1     | 0.10| -10.65| Hs.534797 NM_01903 |
| CTNN2D     | 2.16| 2.16 | Hs.314543 NM_001332 |
| ITGB2      | 0.43| -2.34| Hs.375957 NM_000211 |
| KAL1       | 0.48| -2.08| Hs.521869 NM_000216 |
| LAMA3      | 0.41| -2.46| Hs.436367 NM_000227 |
| MMP2       | 2.70| 2.70 | Hs.513617 NM_004530 |
| MMP3       | 6.37| 6.37 | Hs.375129 NM_002422 |
| MMP7       | 0.41| 2.44 | Hs.2256 NM_002423 |
| MMP12      | 2.74| 2.74 | Hs.1695 NM_002426 |
| MMP13      | 0.47| -2.14| Hs.2936 NM_002427 |
| SELE       | 3.49| 3.49 | Hs.89546 NM_000450 |
| SPARC      | 0.24| -4.16| Hs.111779 NM_003118 |
| TGFB1      | 0.34| -2.92| Hs.369397 NM_000358 |
| THBS3      | 0.38| -2.60| Hs.169875 NM_007112 |
| VCAN       | 0.35| -2.82| Hs.643801 NM_004385 |

Gene expression was assessed using an RT2 Profiler PCR array. SM, cigarette smoke medium; FC, fold change; FR, fold regulation; RT, reverse transcription; CAMs, cell adhesion molecules; ECM, extracellular matrix; PCR, polymerase chain reaction; CLEC3B, c-type lectin domain family 3; CNTN1, contactin 1; COL1A1, collagen type I α 1; CTGF, connective tissue growth factor; CTNNA1, catenin α 1; CTNN2D, catenin Δ 2; ITGB2, integrin β 2; KAL1, kallmann syndrome 1 sequence; LAMA3, laminin α 3; MMP, matrix metallopeptidase; SELE, selectin E; SPARC, secreted protein acidic, cysteine-rich; TGFB1, transforming growth factor, β-induced; THBS3, Thrombospondin 3; and VCAN, Versican.
YANG et al.: CIGARETTE SMOKE MODULATES MIGRATION OF PC3 PROSTATE CANCER CELLS

In order to investigate the effect of SM on the expression of ECM- and of CAM-related genes, PC3 cells were incubated in a starvation medium (0.5% FBS) for 24 h and then treated with 0.5% SM or 0% SM (negative control) for a further 24 h. Of the 84 genes, the expression of 23 (27.38%) exhibited a fold change (FC) value of $\geq 2$ (Table I). These genes included: C-type lectin domain family 3; collagen type I $\alpha_1$ (COL1A1); COL5A1; COL11A1; COL14A1; COL16A1; contactin 1; connective tissue growth factor (CTGF); catenin, $\alpha_1$; catenin $\Delta_2$; integrin $\beta_2$ (ITGB2); kallmann syndrome 1 sequence (KAL1); laminin $\alpha_3$ (LAMA3); matrix metallopeptidase 2 (MMP2); MMP3; MMP7; MMP12; MMP13; selectin E; secreted protein acidic, cysteine-rich (SPARC); transforming growth factor, $\beta$-induced; Thrombospondin 3 (THBS3); and Versican (VCAN).

SM, cigarette smoke medium; FC, fold change; FR, fold regulation; CI, confidence interval; CAMs, cell adhesion molecules; ECM, extracellular matrix; qPCR, quantitative transcription-polymerase chain reaction; COL5A1, collagen type V $\alpha_1$; CTGF, connective tissue growth factor; ITGB2, integrin, $\beta_2$; KAL1, kallmann syndrome 1 sequence; LAMA3, laminin $\alpha_3$; MMP, matrix metallopeptidase; SPARC, secreted protein acidic, cysteine-rich; THBS3, Thrombospondin 3; and VCAN, Versican.

Table II. SM-modulated changes in gene expression of CAMs and ECM-related molecules using qPCR analysis.

| Gene          | FC   | 95% CI       | P-value     | FR   |
|---------------|------|--------------|-------------|------|
| COL5A1        | 0.25 | (0.08, 0.42) | 0.048875    | -2.17|
| CTGF          | 0.31 | (0.21, 0.41) | 0.000417    | -3.24|
| ITGB2         | 0.36 | (0.30, 0.42) | 0.000338    | -2.74|
| KAL1          | 0.26 | (0.07, 0.45) | 0.049642    | -3.91|
| LAMA3         | 0.24 | (0.15, 0.33) | 0.001575    | -4.19|
| MMP2          | 1.28 | (1.08, 1.48) | 0.042917    | 1.28 |
| MMP7          | 0.44 | (0.27, 0.61) | 0.027884    | -2.26|
| MMP12         | 3.47 | (1.74, 5.20) | 0.009610    | 3.47 |
| MMP13         | 0.48 | (0.37, 0.59) | 0.007994    | -2.26|
| SPARC         | 0.15 | (0.11, 0.19) | 0.001258    | -6.59|
| THBS3         | 0.14 | (0.09, 0.19) | 0.004143    | -7.35|
| VCAN          | 0.78 | (0.69, 0.87) | 0.015940    | -1.28|

Analysis of SM-modulated changes in the expression of CAM and ECM-related genes. Genes with an FR of $\geq 2$ (Table II) were sorted into subgroups. CAMs were divided into the following subgroups: Transmembrane molecules (TM); cell-to-cell adhesion molecules (CCA); cell matrix adhesion molecules (CMA); and other adhesion molecules (OAM). ECM-related molecules were divided into the following subgroups: Basement membrane constituents (BMC); collagens and extracellular matrix structural constituents (CEC); extracellular matrix proteases (ECP); extracellular matrix protease inhibitors (ECPI); and other ECM (OECM). SM altered the expression of 18.39% (16/87) of the CAM-related genes (Fig. 2A). The FR of 6.45% (2/31) of TM, 22.22% (2/9) of CCA, 9.52% (2/21) of CMA and 38.46% (10/26) of OMA genes was altered by $\geq 2$ in the SM group compared with the control group (Fig. 2B). SM treatment altered the expression of 33.92% (19/56) of ECM-related genes (Fig. 3A). The FR of 22.22% (2/9) of BMC, 42.85% (6/14) of CEC, 27.77% (5/18) of ECP, 25% (1/4) of ECPI and 45.45% (5/11) of OECM genes was altered in the SM-treated group compared with the control group (Fig. 3B).

Validation of SM-modulated changes in gene expression. SM-treated and control PC3 cells were harvested. RNA was then extracted, purified and subjected to qPCR analysis using the primer sets provided in Table III. Ct values were normalized to those of GAPDH. Statistically significant differences in gene expression in SM-treated compared with control samples were determined using Student’s t-test, and calculated with a 95% confidence interval. SM significantly increased MMP2 and MMP12 expression, and significantly decreased COL5A1, CTGF, ITGB2, KAL1, LAMA3, MMP7, MMP13, SPARC, THBS3 and VCAN expression in PC3 cells compared with that in control cells. The data suggest there may be a correlation between SM-induced migration (Fig. 1) and changes in the expression of ECM- and CAM-related genes. These

![Figure 1. SM-mediated migration of PC3 cells assessed using a wound-healing assay. Data are presented as the number of migrating cells per SM concentration and represent the mean ± standard deviation of the number of migrating cells. *P<0.01 of control cells vs. SM-treated cells. SM, cigarette smoke medium.](image)
changes in gene expression may be associated with interactions between CAM- and ECM-related molecules, which may lead to SM-enhanced migration of PC3 cells.

Table III. List of quantitative polymerase chain reaction primers.

| Gene      | Forward primer                     | Reverse primer                  |
|-----------|------------------------------------|---------------------------------|
| COL5A1    | 5'-TGTATTTCCCCTGACCTTCA-3'         | 5'-ACCTTTAATCCATCGGGAA-3'       |
| CTGF      | 5'-TTTGGCCAGACAACACTAT-3'          | 5'-GCAGGAGGAGTCGTAGG-3'         |
| ITGB2     | 5'-ACAAGCTGGGCTGAAAACAC-3'         | 5'-GTTCTTTGTTTTGGAACA-3'        |
| KAL1      | 5'-CAGCAAAACACTTCGATCTTCT-3'       | 5'-ACTTGCAATCTCCCACTTG-3'       |
| LAMA3     | 5'-CTGCCAGTGCATCTGAATCT-3'         | 5'-ATCCATCTGATCAGCAAC-3'        |
| MMP2      | 5'-TTGACGGTAAAGGAGGACTC-3'         | 5'-ATACGGTTGGAAGTCTTG-3'        |
| MMP7      | 5'-AGCCAAACTCAAGGAGAT-3'          | 5'-GGGAATGTCAAGAATTG-3'         |
| MMP12     | 5'-ACACATTTGCCTCTCCTGTCT-3'        | 5'-ACACATTTGCCTCTCCTGTCT-3'     |
| MMP13     | 5'-TGACCCCTTCTATATCCCTTG-3'        | 5'-ATACGGTTGGAAGTCTTG-3'        |
| SPARC     | 5'-GCACGGGACTGTCAGTTCTCT-3'        | 5'-AAGAACACCCGATTCACAA-3'       |
| THBS3     | 5'-ACACAGTCTCTCCGAGACTC-3'         | 5'-ATACGGTTGGAAGTCTTG-3'        |
| VCAN      | 5'-TTGCTGTGGAAGGAACTTGAG-3'        | 5'-ATACGGTTGGAAGTCTTG-3'        |

COL5A1, collagen type V α1; CTGF, connective tissue growth factor; ITGB2, integrin, β2; KAL1, kallmann syndrome 1 sequence; LAMA3, laminin α3; MMP, matrix metallopeptidase; SPARC, secreted protein acidic, cysteine-rich; THBS3, Thrombospondin 3; and VCAN, Versican.

Figure 2. Effect of SM on the expression of CAM-related genes assessed using an RT² Profiler polymerase chain reaction Array. (A) Percentage of CAM-related genes in which the FR was ≥2.0 following SM treatment, and the percentage of those in which the expression was not affected by SM treatment. (B) Percentage of genes from each CAM-related subgroup in which the FR was ≥2.0 following SM treatment and the percentage of those in which expression was not affected. CAM, cell adhesion molecules; TM, transmembrane molecules CCA, cell-to-cell adhesion; SMA, cell matrix adhesion molecules; OAM, other adhesion molecules; SM, cigarette smoke medium; FR, fold regulation.

Figure 3. Effect of SM on the expression of ECM-related genes assessed using an RT² Profiler PCR Array. (A) Percentage of ECM-related genes in which the FR was ≥2.0 following SM treatment, and the percentage of those in which expression was not affected by SM. (B) Percentage of genes from each ECM-related subgroup in which the FR was ≥2.0 following SM treatment, and the percentage in which expression was not affected. BMC, basement membrane constituent; ECM, extracellular matrix; CEC, collagens and ECM structural constituents; ECP, extracellular proteases; ECPi, ECP inhibitors; OEM, other ECM molecules; SM, cigarette smoke medium; FR, fold regulation.

MMP2-modulated migration of SM-treated PC3 cells. SM treatment led to an increase in the number of migrating PC3 cells (Fig. 1) and enhanced the expression of a number of MMPs,
including MMP2 (Tables I and II). In order to confirm that the increase in MMP2 expression contributed to enhanced PC3 cell migration, PC3 cells were transfected either with a scrambled siRNA (siCTL) or with MMP2 siRNA (siMMP2), which inhibited MMP2 expression. Following 24 h of transfection, a reduction in MMP2 expression was measured using western blot analysis (data not shown). Following 24 h incubation in 0.5% FBS medium, the monolayer was 'wounded' and treated with 0.5% SM for 12 h. Migration of the siMMP2-transfected PC3 cells (with reduced MMP2 expression) was 68% lower than that of siCTL transfected PC3 cells (Fig. 4A and B). These data suggest that SM-enhanced MMP2 expression may contribute to the migration of PC3 cells.

Discussion

A recent observational cohort study demonstrated that smoking is associated with the progression rather than the incidence of PCa (7). However, to the best of our knowledge the underlying molecular mechanism of PCa progression is yet to be investigated. A previous study suggested that cigarette smoke enhanced the growth of PCa cells and increased secretion of VEGF, a potent angiogenic factor (26). In the present study SM treatment led to an increase in PC3 cell migration (Fig. 1). Therefore, exposure to cigarette smoke may accelerate PCa progression. These results are consistent with previous findings, which suggest that smokers exhibit a higher risk of developing advanced stage and high-grade PCa, and report an increased mortality among heavy smokers (7).

The results of the present investigation suggested that PCa cell growth and migration was greater following 0.5% SM treatment compared with that of PCa cells treated with 0.2, 1 and 2% SM (26; Fig. 1), which suggests that 0.5% is an optimal concentration with which to enhance PCa progression. This optimal SM concentration is estimated to contain levels of TPMs, nicotine, and CO, which are equivalent to those found in 1/100 smoke produced by one reference cigarette, according to the Reference Cigarette Program. Cigarette smoke also contains VOCs and reactive free radicals (24,26), which can dysregulate healthy physiological processes, and promote the proliferation, migration, invasion and metastasis of cancer cells (25). Chronic exposure to cigarette smoke, even at low doses, may pose a risk for advanced stage and high-grade PCa in smokers and non-smokers.

Changes in the expression of ECM- and CAM-related genes may alter the interactions of these molecules, influencing PCa progression (43,44). An RT2 Profiler PCR array analysis of PC3 cells suggested that 0.5% SM led to a ≥2-FC change in the expression of 23 out of 84 ECM- and CAM-related genes in PC3 cells (Table I). This is consistent with the results of the PCR analysis conducted in the present study.

The amplitude and type of expression change in ECM- and CAM-related genes varies between disease groups and disorders (38). The transition from healthy epithelial cells to PC3 cells is associated with a decrease in ITGB4 and MMP7 expression, and the transition from prostatic intraepithelial neoplasia to PCa is associated with a downregulation in COL6A1 and ITGB2 expression (38). Loss of the cell adhesion molecule, LAMA3, is associated with high Gleason scores, elevated preoperative PSA levels and advanced stages of PCa (39). Reduced CTGF expression promotes cell growth, migration and invasion of nasopharyngeal carcinoma (45). Elevated COL11A1 expression is detected malignant lesions of the stomach (46) and in sporadic colorectal tumors (47). COL11A1 also promotes tumor progression and is associated with a poor survival outcome in patients with ovarian cancer (48). Among ECM-related genes, an increase in MMP2 expression promotes cell invasion and PCa progression (35-37), and an upregulation of MMP12 is associated with the degradation and invasion of type I collagen in PCa cells (49). In accordance with previous reports (35-37,46-49), the results of the present study suggested that SM treatment enhances the expression of COL11A1, MMP2 and MMP12 in PC3 cells (Tables I and II). These finding suggested that SM-mediated alteration of these molecules may be associated with the progression of PCa.

To the best of our knowledge, the present study was the first to examine the direct effects of cigarette smoke on PCa progression. The results of the present study are consistent with those of with epidemiological studies linking cigarette smoking
to PCa progression. CAM- and ECM-related genes may serve as biomarkers for understanding PCa progression in smokers. In addition, the present study suggested that MMP inhibitors may be useful therapeutic treatments to prevent PCa progression.

Acknowledgements

This study was supported by grants from the Flight Attendant Medical Research Institute (S.S) and National Institutes of Health [grant no. 2R56HL09211 (S.T.).]

References

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Chan JM, Jou RM and Carroll PR: The relative impact and future burden of prostate cancer in the United States. J Urol 172: S13-S16, 2004.
3. Huncharek M, Haddock Ks, Reid R and Kapelnick B: Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 100: 693-701, 2010.
4. Stewart S L, Cardinez CJ, Richardson LC, et al: Surveillance for cancers associated with tobacco use - United States, 1999-2004. MMWR Surveil Summ 57: 1-33, 2008.
5. Colditz G: Consensus conference: smoking and prostate cancer. Cancer Causes Control 7: 560-562, 1996.
6. Hickey K, Do KA and Green A: Smoking and prostate cancer. Epidemiol Rev 23: 115-125, 2001.
7. Rohrmann S, Linsenise J, Allen N, et al: Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 108: 708-714, 2013.
8. Zu K and Giovannucci E: Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 20: 1799-1810, 2009.
9. Roomi MW, Kalinovsky T, Rath M, et al: Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Oncol Rep 26: 1407-1413, 2011.
10. Yurchenco PD and Schritty JC: Molecular architecture of basement membranes. FASEB J 4: 1577-1590, 1990.
11. Barsky SH, Siegel GP, Jannotta F, et al: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1983.
12. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
13. Liotta LA, Rao CN and Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 636-649, 1983.
14. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
15. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
16. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
17. Nelson AR, Fingleton B, Rothenberg ML, et al: Stromal cells enhance prostate cancer cell invasion through type I collagen. Cell Mol Life Sci 66: 345-357, 2009.
18. Nabha SM, dos Santos EB, Yamamoto HA, et al: Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 122: 2482-2490, 2008.